Regeneron has announced that the European Commission ... Gynaecological Oncological Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old – 78% with ...

Feb 24 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...